Anteris Technologies Global Corp. — Capital/Financing Update 2016

Nov 20, 2016

REGISTERED OFFICE: 26 Harris Road Malaga Western Australia 6090

==> picture [226 x 82] intentionally omitted <==

Admedus Ltd ABN 35 088 221 078

ASX ANNOUNCEMENT

PO Box 6879 East Perth Western Australia 6892 T +61 (0)8 9266 0100 F +61 (0)8 9266 0199 E info.au@admedus.com

www.admedus.com

CARDIOCEL[®] RECEIVES MARKET APPROVAL IN UAE

• Admedus and partner Genpharm receive marketing approval in UAE

• Initial orders for CardioCel[®] in UAE received

• Part of continued expansion in emerging markets

Brisbane, Australia 21[st] November, 2016

Admedus Limited (ASX: AHZ) today announced that, in collaboration with its regional partner Genpharm, it has received market approval for CardioCel[®] in the United Arab Emirates (UAE) and first orders. This follows on from the recent approval of the product in Kuwait.

“As we continue to drive strong sales growth of CardioCel[®] , this approval is a significant milestone in terms of our expansion of the product franchise across emerging markets. The UAE is a strategically important location as a central hub in MENA for performing cardiovascular surgery” stated Chair and Interim CEO, Mr Wayne Paterson.

CardioCel[®] is a single-ply bio-scaffold that remains functional, durable and free from calcification. Engineered with Admedus’ proprietary ADAPT[®] technology, CardioCel[®] provides superior restorative structural heart repair and reconstruction. Long-term clinical studies using CardioCel[®] have shown no calcification eight years’ postimplantation. CardioCel[®] is used in leading heart centers around the world for cardiovascular repairs and reconstructions.

The UAE has over 500 cases of congenital defects per annum and an increasing number of older patients with congenital defects seeking repair. The UAE is also an important regional hub for cardiovascular surgery and healthcare in general.

“This is an important product approval for both cardiac surgeons and their patients in the UAE and beyond. Bringing cutting edge medical products to the MENA region is one of our primary goals and we are delighted, therefore, to announce the approval of CardioCel[®] in the region” said Mr Karim Smaira, Managing Partner, Genpharm .

Admedus and Genpharm were well represented at the fifth scientific meeting for the World Society of Paediatric and Congenital Heart Surgery (WSPCHS) held in Abu Dhabi in October 2016.

==> picture [595 x 44] intentionally omitted <==

==> picture [170 x 63] intentionally omitted <==

Follow us:

Twitter: @Admedus Facebook: www.facebook.com/pages/Admedus Website: www.admedus.com Blog: www.admedus.com/au/category/news/

For more information, please contact:

Dr Julian Chick | Chief Operating Officer | Admedus Limited Tel: +61 (0)8 9266 0100

Media Europe

FTI Consulting Simon Conway / Victoria Foster Mitchell Tel: +44 (0) 20 3727 1000 admedus@fticonsulting.com

US Investor

Rx Communications Group, LLC Melody A. Carey +1 917 322 2571 mcarey@rxir.com

About Admedus Limited

Admedus (ASX: AHZ) is a specialist healthcare company. Our focus is on investing in and developing next generation technologies with world class partners, acquiring strategic assets to grow product and service offerings and expanding revenues from our existing, profitable medical sales and distribution business. The company has assets from research & development through clinical development as well as sales, marketing and distribution.

Admedus has commercialised its innovative tissue engineering technology for regenerative medicine in four continents. We also have a major interest in developing the next generation of vaccines with a Brisbane-based research group led by Professor Ian Frazer. The vaccine programmes target disease with significant global potential, such as Herpes and Human Papillomavirus.

Further information on the company can be found on www.admedus.com

About CardioCel[®]

CardioCel[®] is a single-ply bio scaffold that remains functional, durable and free from calcification. Engineered with Admedus’ proprietary ADAPT technology, CardioCel[®] provides superior restorative structural heart repair and reconstruction. Long-term clinical studies using CardioCel[®] have shown no calcification eight years’ postimplantation. CardioCel[®] is used in leading heart centers around the world.

CardioCel[®] benefits include:

Optimized Clinical Performance CardioCel[®] is indicated for use in pericardial closure and the repair of cardiac and vascular defects including intracardiac defects; septal defects; valve and annulus repair; great vessel reconstruction, peripheral vascular reconstruction and suture line buttressing.

• Strong, durable aldehyde-free repair

• Time-dependent controlled restoration, free from calcification and graft failure

• Terminally sterilized for reduced risk of infection

Enhanced Procedural Efficiency

• Ready to use off the shelf

• Excellent haemostasis—resists suture line bleeding

==> picture [170 x 63] intentionally omitted <==

• Broadest indication for your cardiovascular needs

Improved Handling Characteristics

• Elasticity and strength facilitates dynamic and static cardiovascular repair

• • Pliability that provides you with optimal tactile experience

• Responsive to your skilful control

CardioCel[®] is indicated for use in pericardial closure and the repair of cardiac and vascular defects including intracardiac defects; septal defects; valve and annulus repair; great vessel reconstruction, peripheral vascular reconstruction and suture line buttressing.